Balchem (NASDAQ:BCPC), through its subsidiaries, develops, manufactures and markets specialty performance ingredients and products that enhance the nutritional, health and safety attributes of products in human and animal nutrition, pharmaceuticals and food industries. Founded in 1967 and headquartered in New Hampton, New York, the company has built a reputation for expertise in microencapsulation, matrix technologies and controlled-release delivery systems.
The company operates across three primary segments: human nutrition and health, animal nutrition and health, and food and industrial specialties. In human nutrition, Balchem produces choline chloride, betaine and other dietary supplements, along with vitamin D3 and K2 formulations designed to support bone and cardiovascular health. Its animal nutrition segment offers rumen-protected amino acids and mineral systems to improve livestock performance and feed efficiency, as well as specialty nutrients for companion animals. The food and industrial specialties segment supplies pasteurization salts, flavor- and aroma-protecting encapsulated ingredients and process aids for food manufacturers and industrial applications.
Balchem maintains a global footprint with manufacturing and research facilities in North America, Europe and Asia, enabling responsive supply chains and regulatory compliance across key markets. The company has pursued targeted acquisitions and ongoing investments in research and development to expand its product portfolio and strengthen its technological capabilities. Under the leadership of President and Chief Executive Officer Mark J. A. Garrett, Balchem continues to focus on innovation, operational excellence and sustainable growth within its core business areas.
